伊利替康联合顺铂治疗晚期非小细胞肺癌的疗效观察

Observation of the curative effect of irinotecan HCL trihydrate combination with cisplatin in treatment of non-small cell lung cancer

目的 探讨盐酸伊利替康联合顺铂治疗非小细胞肺癌（NSCLC）的临床疗效及不良反应.方法 非小细胞肺癌患者120例,随机分为观察组和对照组,观察组60例采用盐酸伊利替康联合顺铂化疗方案,对照组采用顺铂联合依托泊苷方案,评定治疗效果.结果 观察组总有效率为56.7%,明显高于对照组的41.7%（χ^2=2.700,P＜0.05）;观察组平均生存时间为（9.3±4.2）个月,明显长于对照组的（7.2±3.2）个月（P＜0.05）.按照Kamofsky分级标准,观察组化疗后总体有效率76.7%,明显优于对照组的56.7%（χ^2=5.400,P＜0.05）.结论 盐酸伊利替康联合顺铂治疗NSCLC不仅疗效显著,且可有效降低毒性反应,提高患者生存质量.

Objective To explore the clinical curative effect of irinotecan HCL trihydrate combination with cisplatin in treatment of non.small-cell carcinoma（NSCC）by observing the clinical curative effect,adverse reactions and the improvement of the quality of life post therapy.Methods 120 patients with NSCC were divided into two groups.60 cases in control group were treated with cisplatin and topotecan while ifinotecan HCL tfihydrate combination with cisplatin chemotherapy for 60 case of patients in observation group.The curative effect and Kamtfsky point were observed.Results The effective rate of observation group was 56.7%,which was significantly higher than that of the control group（41.7%）,and differences between the two groupswas statistically significant（P〈0.05）.Average survival time for treatment group was（9.3±4.2）months that was longer than that of the control group[（7.2±3.2）months]（P〈0.05）.The result of Kamofsky classification standard after chemotherapy also indicated the same situation（P〈0.05）.Conclusion Irinotecan HCL trihydrate combining with cisplatin in treatment of non-small cell lung cancer had a effective therapy result and could reduce the toxicity.as well as improving the quality of life of the patients.